Novozymes’ hyaluronic acid is presently being sold to medical device and pharma customers.
Novozymes executive vice president Thomas Videbæk said the shipment of first commercial hyaluronic acid material has begun at the company’s new facility.
"Not only is Hyasis manufactured in accordance with the requirements for an active pharma ingredient, it also offers unrivalled safety, consistency and performance for the benefit of our customers and partners," Videbæk added.
The new facility is in accordance with the highest pharma standards, Q7 cGMP, the company said.
Novozymes’ Bacillus-based process removes the risks of associated with a number of potential challenges such as risk of viral contamination or contamination with other impurities such as endotoxins.
Hyaluronic acid is a naturally occurring substance that is distributed widely in the human body and provides structure to tissues, including skin and cartilage.